Clinical and Experimental Hypertension (Oct 2019)

Renal effects of sodium glucose co-transporter 2 inhibitors in Japanese type 2 diabetes mellitus patients with home blood pressure monitoring

  • Kazuo Kobayashi,
  • Masao Toyoda,
  • Moritsugu Kimura,
  • Nobuo Hatori,
  • Takayuki Furuki,
  • Hiroyuki Sakai,
  • Masahiro Takihata,
  • Tomoya Umezono,
  • Shun Ito,
  • Daisuke Suzuki,
  • Hiroshi Takeda,
  • Akira Kanamori,
  • Hisakazu Degawa,
  • Hareaki Yamamoto,
  • Hideo Machimura,
  • Atsuko Mokubo,
  • Keiichi Chin,
  • Mitsuo Obana,
  • Toshimasa Hishiki,
  • Kouta Aoyama,
  • Shinichi Nakajima,
  • Shinichi Umezawa,
  • Hidetoshi Shimura,
  • Togo Aoyama,
  • Kazuyoshi Sato,
  • Masaaki Miyakawa

DOI
https://doi.org/10.1080/10641963.2018.1529778
Journal volume & issue
Vol. 41, no. 7
pp. 637 – 644

Abstract

Read online

Decrease in blood pressure contributes to the reno-protective effects of sodium-glucose cotransporter 2 inhibitors; however, its relationship with home monitoring of blood pressure is unclear. We retrospectively analyzed 101 visiting members of the Kanagawa Physicians Association with type 2 diabetes mellitus and chronic kidney disease who were taking sodium-glucose cotransporter 2 inhibitors and who monitored blood pressure at home for a median treatment period of 14 months. At baseline, the mean value of HbA1c was 59.3 mmol/mol (7.6%) and the median value of albumin-creatinine ratio was 30.9 mg/gCr that was evaluated in 88 patients. The mean blood pressure both at office and home significantly decreased, and there was a significant positive correlation between the change in albumin–creatinine ratio and both blood pressures. Controlled hypertension, masked hypertension, white coat hypertension, and sustained hypertension were observed in 10.9%, 13.9%, 12.9%, and 62.4% of patients at the initiation of therapy, which changed to 10.9%, 16.8%, 17.8%, and 54.5% at the time of the survey, respectively. In conclusion, management of blood pressure both at office and home was found to be important for the reno-protective effects of sodium-glucose cotransporter 2 inhibitors along with strict blood pressure management.

Keywords